Halozyme Therapeutics Q2 Adj $0.91 Beats $0.78 Estimate, Sales $231.35M Beat $208.90M Estimate
Author: Benzinga Newsdesk | August 06, 2024 04:02pm
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.78 by 16.67 percent. This is a 22.97 percent increase over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $231.35 million which beat the analyst consensus estimate of $208.90 million by 10.75 percent. This is a 4.67 percent increase over sales of $221.04 million the same period last year.
Posted In: HALO